How Can CROs Gain Buy-in from Pharma for Investment in R&D Innovation?
Growth by Acquisition in Life Sciences: Do You Have a Plan?
As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as Roche’s acquisition of Ariosa Diagnostics and LabCorp’s acquisition of Covance, bring to light an important question for decision makers in the life sciences industry: When it comes to growth by acquisition, what is your plan? … Continue reading Growth by Acquisition in Life Sciences: Do You Have a Plan?
Driving Revenue and EBIDTA at CROs through Customer Loyalty
Determining customer satisfaction and loyalty is a difficult endeavor for most businesses. Traditional voice of customer surveys are often laborious, complex and yield ambiguous results. For life sciences organizations, particularly clinical research organizations (CROs), this process is especially complex. The pay-off for CROs can be significant though. At Kineticos, we’ve seen revenue and … Continue reading Driving Revenue and EBIDTA at CROs through Customer Loyalty
Foundation Medicine and Clovis Expand Partnership
In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion diagnostic for a Clovis drug currently in clinical trials.1 Specifically, the test is being developed in conjunction with the FDA new drug application submission for Rucaparib, a polymerase inhibitor for the treatment of…
LabCorp to Acquire LipoScience
Laboratory Corporation of America Holdings is making a strong bid to expand its personalized medicine offering by adding LipoScience to its arsenal of specialty lab…
ICON and Medidata Partner to Offer Electronic Patient Reported Outcomes
Over the past year, I have written many blogs about building partnerships with external service providers. When we see major life science organizations engaging in strategic partnerships within the life sciences ecosystem, it is important to…
NICE’s New Clinical Data Requirement: Effect on Biomarker Use in Clinical Trials?
The UK’s NICE (National Institute for Health and Care Excellence) has for some time been the leader among health technology assessment groups, evaluating the cost-benefit ratio for new drugs, tests and devices. While NICE has only specific authority in the UK, there is no question that both formally and informally it strongly influences…